IMV Inc. Announces Update on CCAA Proceedings and Sales and Investment Solicitation ProcessBusiness Wire • 07/26/23
IMV Initiates Restructuring Proceedings Under the CCAA to Complete the Review of its Strategic AlternativesBusiness Wire • 05/01/23
IMV Inc. Announces Strategic Update as well as Fourth Quarter and Full Year 2022 Financial and Operational ResultsBusiness Wire • 03/16/23
IMV Inc. to Announce Fourth Quarter and Fiscal Year 2022 Results and Host a Conference Call and Webcast on March 16, 2023Business Wire • 03/09/23
IMV Inc. Presents Positive Initial Results From The MVP-S Phase 2B VITALIZE TrialBusiness Wire • 02/13/23
IMV Inc. Announces Update and Planned 2023 Milestones to Advance Clinical Development of its Lead Therapeutic, MVP-SBusiness Wire • 01/08/23
IMV Announces Closing of US$9 Million Registered Direct Offering Priced At-The-Market Under Nasdaq RulesBusiness Wire • 12/20/22
IMV Announces US$9 Million Registered Direct Offering Priced At-The-Market Under Nasdaq RulesBusiness Wire • 12/16/22
IMV Inc. Announces Initial Data from the Ongoing Phase 2B VITALIZE Trial in Patients with r/r DLBCLBusiness Wire • 12/15/22
IMV Inc. to Announce Third Quarter 2022 Results and Host a Conference Call and Webcast on November 11, 2022Business Wire • 11/08/22